Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris

First Page		Document Content
Date: 2016-05-16 12:22:49 Anatomy Medicine Clinical medicine Blood disorders Acquired hemolytic anemia Nephrology Organ failure Hemolytic-uremic syndrome Syndromes Atypical hemolytic uremic syndrome Thrombotic microangiopathy Eculizumab		Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris Add to Reading List Source URL: www.hemapherese.fr Download Document from Source Website File Size: 1,05 MB Share Document on Facebook

	Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris DocID: 1pPKn - View Document
	HUS ParisMode de compatibilité] DocID: 1oXIv - View Document
	Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report DocID: 15RF1 - View Document
	Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit DocID: 11QLO - View Document
	Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefi DocID: 104ng - View Document